Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Patients

NCT07472673 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai Mental Health Center

Phase

Not applicable

Started

2026-02-15

Last updated

2026-03-16

Condition(s) studied

Alcohol Use Disorder

Investigational drug(s) / intervention(s)

tTIS on Amygdala, 10 HztTIS on Amygdala, Sham

tTIS on Amygdala, 10 Hz: Through the transcranial electric stimulation device, the first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2.010 kHz. According to the principle of time-domain coherence, an alternating electric field with a frequency of f2-f1 = 10 Hz can be generated in the target area. The optimal electrode position and current parameters are determined by using the individualized modeling. For each participant, the current intensity was determined via electric field simulation to implement an individualized intervention protocol.

tTIS on Amygdala, Sham: The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2 kHz. The optimal electrode position and current parameters are determined by using the individualized modeling. For each participant, the current intensity was determined via electric field simulation to implement an individualized intervention protocol.

Study summary

The purpose of this research is to investigate the efficacy of transcranial temporal interference stimulation (tTIS) targeting the amygdala in patients with alcohol use disorder.

Eligibility

Sex

MALE

Min age

18 Years

Max age

60 Years

Healthy volunteers

Inclusion Criteria: * aged 18 to 60 years old; * Meets the DSM-5 diagnostic criteria for alcohol use disorder; * Normal or corrected normal vision and hearing; * Able to cooperate in completing the questionnaire assessment and behavioral tests; * No metal implantation in the head, no history of neurological problems or head injury. Exclusion Criteria: * Suffering from severe cognitive dysfunction, such as a history of head trauma, cerebrovascular disease, epilepsy, etc., use of cognitive-promoting medications in the last 6 months; * serious physical or neurological illness, a diagnosis of any other psychiatric disorder under DSM-5 criteria (except for nicotine use disorder); Other psychoactive substance abuse or dependence in the last 5 years (except nicotine). * any contraindications to transcranial electrical stimulation.

Primary outcome measure(s)

Change of Craving assessed by Visual Analog Scale — Reported by participants before and after intervention, as well as during the 1 and 4 weeks follow-up period.
evaluate all participants' craving for for alcohol assessed by Visual Analog Scales (VAS). Score of VAS range from 0 to 100, and higher values represent high level of craving.

Trial sites (1)

Facility	City	Region	Status
Shanghai Mental Health Center	Shanghai	China

More Shanghai Mental Health Center trials in China

The Effect of Game-Based Intervention on the Cognition of Schizophrenia Patients Recruiting

The Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder Recruiting

High Intensity Alternating Current Stimulation as a Neuromodulation Therapy for Alcohol Use Disorder: A Pilot Study Starting soon

Unique Electroencephalography (EEG) Markers of Habit Behaviors in Obsessive-Compulsive Disorder (OCD) Enrolling by invitation

A Study on the Preference of Risperidone Dosage Forms Recruiting

Other trials for the same condition

A Study of Brenipatide in Participants With Alcohol Use Disorder Recruiting

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder Recruiting

HD-tACS for Alcohol Use Disorder Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07472673 on ClinicalTrials.gov ↗ ← All trials in China